Edition:
United States

Eaton Corporation PLC (ETN)

ETN on New York Consolidated

66.51USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$66.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,769,277
52-wk High
$68.95
52-wk Low
$46.19

ETN

Chart for ETN

About

Eaton Corporation plc is a power management company. The Company provides energy-efficient solutions that help its customers to manage electrical, hydraulic and mechanical power. It operates in four segments: Electrical Products and Electrical Systems and Services, Hydraulics, Aerospace and Vehicle. The Electrical Products... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $29,604.42
Shares Outstanding(Mil.): 451.70
Dividend: 0.57
Yield (%): 3.48

Financials

  ETN Industry Sector
P/E (TTM): 15.43 24.01 68.10
EPS (TTM): 4.25 -- --
ROI: 7.27 10.20 5.65
ROE: 12.67 11.80 7.03

BRIEF-Eaton Corp reports Q3 operating earnings per share $1.15

* Eaton reports third quarter net income and operating earnings per share of $1.15

Nov 01 2016

BRIEF-Eaton Q2 operating earnings per share $1.07

* Eaton reports second quarter net income and operating earnings per share of $1.07, above midpoint of guidance

Aug 02 2016

BRIEF-Eaton Corporation says board expanded its size to fourteen members

* Says board expanded its size to fourteen members and elected Dorothy C. Thompson to fill the vacancy - sec filing Source - http://bit.ly/2aBOeuy Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Jul 29 2016

World champions Barber and Drouin lead Canadian team

World champions Shawn Barber and Derek Drouin and heptathlon favorite Brianne Theisen-Eaton headline a 65-member Canadian athletics team for the Rio Olympics announced on Monday.

Jul 11 2016

Athletics-World champions Barber and Drouin lead Canadian team

July 11 World champions Shawn Barber and Derek Drouin and heptathlon favourite Brianne Theisen-Eaton headline a 65-member Canadian athletics team for the Rio Olympics announced on Monday.

Jul 11 2016

BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse

* Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome

Jun 13 2016

Earnings vs. Estimates